Libtayo Gains Approval for First-Line NSCLC With Chemotherapy

Regeneron Pharmaceuticals, Inc.'s PD-1 inhibitor Libtayo (cemiplimab) was late to the market, but has added a new approval for first-line non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, a valuable indication that will make it more competitive with the PD-1/L1 inhibitor market leader, Merck & Co., Inc.'s Keytruda (pembrolizumab).

Libtayo was approved by the US Food and Drug Administration on 8 November for use in combination with platinum-based chemotherapy for the first-line treatment of adults with advanced NSCLC without...